Clinical Trials

For a quick look at enrolling or soon to be enrolling investigational drug studies in Duchenne and their enrollment criteria, check out our Clinical Trial Cheat Sheet below.

Clinical Trial Finder

Use this Clinical Trial Finder below that can help provide you with more information regarding clinical trials in Duchenne that that you, your child, or your patient may be eligible for!

Watch Jett Foundation's Mini Satellite Presentation

Presented by Jean Mah, M.D., Associate Professor of Pediatric Neurology Alberta Children’s Hospital at the 2016 Child Neurology Society Meeting to learn more about these potential therapies!

Latest Duchenne News

April 1, 2024
Pfizer launches Duchenne caregiver education website.
March 22, 2024
Jett Foundation is thrilled to share that the U.S. Food and Drug Administration (FDA) has approved Duvyzat (givinostat) to treat children and adolescents with Duchenne muscular dystrophy (DMD).  Please read...
March 19, 2024
PTC plans to re-submit an NDA for Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy.
March 13, 2024
Following the FDA approval on October 26, 2023, AGAMREE is now available by prescription and dispensed throughout the United States through a specialty pharmacy network.
March 13, 2024
PepGen shares a press release announcing the FDA has granted both orphan drug and rare pediatric disease designations for PGN-EDO51.
March 5, 2024
REGENXBIO reports additional interim safety and efficacy data in the Phase I/II AFFINITY DUCHENNE® trial of RGX-202 in patients with Duchenne.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open